Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.

Also called NCT01758471

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose basic science
Phase
Phase 4
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01758471
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01758471. Randomized; no masking; primary purpose basic science. Start 2012-12 (registry gives no type); primary completion 2013-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes
Intervention (Drug)
Glipizide
Intervention (Drug)
Acarbose
Lead sponsor
Shanghai Jiao Tong University School of Medicine (class: other)

Record details

Record id
cardio:ct-nct01758471
Content hash
ff7565e27faa4899485f389e05410e4ce81a8c67127884a8c5ea9141298b2ff4